Prognostic Value of Melanoma Inhibitory Activity Protein in Localized Cutaneous Malignant Melanoma

Table 2

Disease-free survival (DFS) rate of stages I and II melanoma patients according to MIA serum concentration.

MIA; ng/mL	Number of patients	Number of relapses	1-year; DFS	2-year; DFS	3-year DFS	4-year DFS	Mean DFS (95% CI)	Median DFS (95% CI)
≥9.4	24	16	79.2%	58.3%	35.4%	30.3%	2.4 years; [1.7–2.9]	2.2 years; [0.9–3.5]
<9.4	60	3	98.3%	94.5%	94.5%	94.5%	4.4 years; [4.1–4.6]	—